USA, CANADA, BELGIUM, GERMANY, JAPAN, KOREA, SPAIN, TAIWAN - 26 Nov `18Pfizer: PF-06651600 and PF-06700841

Official Title: A Phase 2B randomized, double-blind, placebo-controlled, multicenter, dose-ranging study to evaluate the efficacy and safety profile of PF-06651600 with a partially blinded extension period to evaluate efficacy and safety of PF-06651600 and PF-06700841 in subjects with active non-segmental vitiligo. 

In Brief: This is a Phase 2b, randomized, double blind, parallel group, multicenter study with an extension period. The study will have a maximum duration of approximately 60 weeks. This includes an up to 4 weeks Screening Period, a 24 week dose ranging period, an up to 24 week extension period and a 8 week Follow up Period.

In Plain English: This trial represents the fruition of years of scientific research to develop this promising drug candidate. The aim of the trial is to evaluate the efficacy and safety of an investigational drug for vitiligo. You may qualify for this study if you:

  • Aged 18-65
  • Have generalized vitiligo for 3 months or more
  • Have active vitiligo lesions on the face or the body.

If you qualify, enrollment will last for up to 60 weeks, or about one year. As part of the study, you will receive all study-related medication and care at no cost to you. You’ll also have appointments at a study clinic near you during your participation. Teams at the trial locations will constantly monitor your health situation to assess the drug safety and see how you’re responding to study drug. A spirit of collaboration binds different institutions and researchers that are conducting the trial in multiple centers across the USA and Canada, and other countries.

Ages Eligible: 18 Years to 65 Years

Start Date: November 26, 2018

Completion Date (estimated): December 14, 2020

Status: Active, recruiting

Study ID from NCT03715829
Other Study ID Numbers: B7981019; 2018-001271-20 (EudraCT Number)

Location: 91 locations across the United States, as well as Australia, Belgium, every province of Canada, Germany, Japan, Republic of Korea, Spain, Taiwan.

Contact: To learn more about this study, you or your doctor may contact Pfizer Clinical Trials Contact Center by phone 1-800-718-1021 or email Please refer to this study by its NCT number.

FAQOther Questions

  • Who is prone to vitiligo?

    Scientists know that some people are genetically predisposed to a specific group of autoimmune diseases – including generalized vitiligo – but do not know who and why.It doesn’t...

  • Is it possible to stop the progression of vitiligo?

    It is true that vitiligo progression could be stopped in 4 out of 5 cases by the use of potent systemic corticosteroids - that is, oral medications. However, systemic corticost...

  • How can I cure vitiligo?

    There is no cure for vitiligo, but there are a number of effective treatment options that can be discussed with your GP or dermatologist. The aim of treatment is to stop new pat...